daratumumab,talquetamab,teclistamab,pomalidomide
janssen,genmab
['trimm-2', 'multiplemyeloma', 'monumental-1', 'janssen']
at janssen, we aim to improve outcomes for patients through our innovative #multiplemyeloma therapies. learn more about our latest data from the phase 2 monumental-1 and phase 1b trimm-2 studies at #asco23: 
At Janssen, we never stop working toward a future where disease is a thing of the past. Channel run by Janssen Global Services LLC, NJ, USA.